Entered into acamedia cache on Juli 17, 2011.

DOE Genomes
skip navigation

Human Genome Project Information

Policies on Release of Human Genomic Sequence Data
Bermuda-Quality Sequence

Basic Information
 Genetics 101
 Media Guide

About the Project
 What is it?
 Landmark Papers
 Sequence Databases
 Ethical Issues
 Genetics 101

Medicine &
the New Genetics

 Gene Testing
 Gene Therapy

 Disease Information
 Genetic Counseling

Ethical, Legal,
Social Issues

 Privacy Legislation

 Gene Testing
 Gene Therapy
 Genetically Modified Food
 Behavioral Genetics
 Minorities, Race, Genetics
 Human Migration

 Chromosome Poster
 Genetics 101
Genética Websites en Español

 Sequence Databases
 Landmark Papers

 Chromosome Poster
 Primer Molecular Genetics
 List of All Publications

  ???Search This Site

 Contact Us
 Privacy Statement

 Site Stats and Credits
 Site Map

Quick links to this page:

Summary of the Report of the Second International Strategy Meeting on Human Genome Sequencing
(Bermuda, 27th February - 2nd March, 1997)
as reported by HUGO

  • The principles enunciated at the first International Strategy meeting, of rapid data release and public access to the primary genomic sequence, were reaffirmed.
  • Scientists and funding agencies should take the necessary steps to ensure that the principles are adhered to by all participating organisations.
Sequence Quality Standards
The following standards were agreed:
  • The nucleotide error rate should be 1 error in 10,000 bases or less for most sequence.
  • Assemblies should be verified by restriction digest using two or more restriction enzymes.
  • Gaps in sequence. The agreed long term goal is no gaps, recognising that this is not yet routine.
  • Closing gaps is the responsibility of the original sequencer.
The following proposals were endorsed by the participants:
  • It was agreed that a useful trial to assess sequence accuracy would be to perform a data exchange exercise. Raw sequence data would be exchanged among sequencing centres, centres would reassemble the data and identify outright discrepancies or ambiguities with reference to the sequence submitted to the database. These would be resolved by further consultation or resequencing. The same data sets would be sent to two centres which would hopefully engender competition to detect errors.
  • All sequence reads should be archived in a retrievable form.
  • Sequencing centres should define explicitly how error rates and costs have been calculated.
Sequence Submission and Annotation
Sequence data should be classified simply as "finished" or "unfinished" and should be stored in distinct databases; consideration should be given to establishing a public database for unfinished sequence data.

Sequence annotation should be standardised if possible, and include the following information:

  • Error estimation such as PHRED AND PHRAP data.
  • Enzymes used to verify assemblies, and sizes of fragments produced.
  • Exact details on how to assemble adjacent clones, with a minimum of 100 bp of overlapping (preferably unique) sequence between clones for verification.
  • Gaps must be sized and the surrounding sequence oriented and ordered. The methods used for sizing, and reasons for not closing the gap should be stated.
  • If features such as coding sequence and splice sites are included in the annotation, it should be stated if they were identified experimentally or by computer predictions.
  • Unfinished sequence; it should be stated how near the sequence is to completion.
Potential development of a database listing all gaps in 'finished' sequence.

Sequence Claims and Etiquette
Mapping investment does not automatically entitle sequencing claims over the same region until a sequence ready map has been generated.

Potential conflicts with other sequencers to be resolved by early communication.

Collaborations with groups with a biological interest in a region should be subject to the same principles of data release and communication.

Investigate whether the Human Sequence Map Index should be relocated to be more closely associated with the other major human sequence databases.

Claims allowed on the Index:

  • Duration - maximum 1 year.
  • Size of region - minimum 1 Mb; regions to be defined by Généthon markers if possible, other agreed and available markers if not.
  • Maximum amount - in the order of three times the sequence released by the centre in the preceding year.
  • Sequence claims must span the entire region between, and including, the delimiting markers.

Summary of Principles Agreed at the First International Strategy Meeting on Human Genome Sequencing
(Bermuda, 25-28 February 1996)
as reported by HUGO

The following principles were endorsed by all participants. These included officers from, and scientists supported by, the Wellcome Trust, the UK Medical Research Council, the NIH NCHGR (National Center for Human Genome Research) , the DOE (U.S. Department of Energy), the German Human Genome Programme, the European Commission, HUGO (Human Genome Organisation) and the Human Genome Project of Japan. It was noted that some centres may find it difficult to implement these principles because of legal constraints and it was, therefore, important that funding agencies were urged to foster these policies.

Primary Genomic Sequence Should be in the Public Domain

It was agreed that all human genomic sequence information, generated by centres funded for large-scale human sequencing, should be freely available and in the public domain in order to encourage research and development and to maximise its benefit to society.

Primary Genomic Sequence Should be Rapidly Released

  • Sequence assemblies should be released as soon as possible; in some centres, assemblies of greater than 1 Kb would be released automatically on a daily basis.
  • Finished annotated sequence should be submitted immediately to the public databases.
It was agreed that these principles should apply for all human genomic sequence generated by large-scale sequencing centres, funded for the public good, in order to prevent such centres establishing a privileged position in the exploitation and control of human sequence information.


In order to promote coordination of activities, it was agreed that large-scale sequencing centres should inform HUGO of their intention to sequence particular regions of the genome. HUGO would present this information on their World Wide Web page and direct users to the Web pages of individual centres for more detailed information regarding the current status of sequencing in specific regions. This mechanism should enable centres to declare their intentions in a general framework while also allowing more detailed interrogation at the local level.

For More Information

Last modified: Wednesday, October 29, 2003

Home * Contacts * Disclaimer

Document Use and Credits
Publications and webpages on this site were created by the U.S. Department of Energy Genome Program's Biological and Environmental Research Information System (BERIS). Permission to use these documents is not needed, but please credit the U.S. Department of Energy Genome Programs and provide the website All other materials were provided by third parties and not created by the U.S. Department of Energy. You must contact the person listed in the citation before using those documents.

Base URL:

Site sponsored by the U.S. Department of Energy Office of Science, Office of Biological and Environmental Research, Human Genome Program